197 related articles for article (PubMed ID: 25637565)
1. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles.
You J; Zhao J; Wen X; Wu C; Huang Q; Guan F; Wu R; Liang D; Li C
J Control Release; 2015 Mar; 202():40-8. PubMed ID: 25637565
[TBL] [Abstract][Full Text] [Related]
2. Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells.
Zhao J; Wu C; Abbruzzese J; Hwang RF; Li C
Mol Pharm; 2015 Jun; 12(6):2093-100. PubMed ID: 25936695
[TBL] [Abstract][Full Text] [Related]
3. Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer.
Chitkara D; Singh S; Kumar V; Danquah M; Behrman SW; Kumar N; Mahato RI
Mol Pharm; 2012 Aug; 9(8):2350-7. PubMed ID: 22780906
[TBL] [Abstract][Full Text] [Related]
4. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging.
Satterlee AB; Yuan H; Huang L
J Control Release; 2015 Nov; 217():170-82. PubMed ID: 26341695
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
6. Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer.
Zhang B; Jiang T; Shen S; She X; Tuo Y; Hu Y; Pang Z; Jiang X
Biomaterials; 2016 Oct; 103():12-21. PubMed ID: 27376555
[TBL] [Abstract][Full Text] [Related]
7. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
[TBL] [Abstract][Full Text] [Related]
8. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
9. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
10. Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.
Koonce NA; Quick CM; Hardee ME; Jamshidi-Parsian A; Dent JA; Paciotti GF; Nedosekin D; Dings RP; Griffin RJ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):588-96. PubMed ID: 26461001
[TBL] [Abstract][Full Text] [Related]
11. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
Persson M; Gedda L; Lundqvist H; Tolmachev V; Nordgren H; Malmström PU; Carlsson J
Cancer Res; 2007 Jan; 67(1):326-31. PubMed ID: 17210714
[TBL] [Abstract][Full Text] [Related]
12. Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma.
Tsai CL; Hsu FM; Tzen KY; Liu WL; Cheng AL; Cheng JC
J Gastroenterol Hepatol; 2015 Aug; 30(8):1317-24. PubMed ID: 25682950
[TBL] [Abstract][Full Text] [Related]
13. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells.
Hu K; Zhou H; Liu Y; Liu Z; Liu J; Tang J; Li J; Zhang J; Sheng W; Zhao Y; Wu Y; Chen C
Nanoscale; 2015 May; 7(18):8607-18. PubMed ID: 25898852
[TBL] [Abstract][Full Text] [Related]
15. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model.
Liu CM; Lee WC; Yu CY; Lan KL; Chang CH; Ting G; Lee TW
Oncol Rep; 2012 Mar; 27(3):678-84. PubMed ID: 22109644
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
[TBL] [Abstract][Full Text] [Related]
20. [
Schottelius M; Osl T; Poschenrieder A; Hoffmann F; Beykan S; Hänscheid H; Schirbel A; Buck AK; Kropf S; Schwaiger M; Keller U; Lassmann M; Wester HJ
Theranostics; 2017; 7(9):2350-2362. PubMed ID: 28744319
[No Abstract] [Full Text] [Related]
[Next] [New Search]
